Cypherpunk Technologies increased its Zcash treasury to 314,185.70 ZEC and invested $5 million in Zcash Open Development Labs to support privacy tech. Its subsidiary Leap Therapeutics received FDA Fast Track for sirexatamab in colorectal cancer and presented positive clinical data. The company reported a $77.2 million net loss in Q1 2026, mainly due to unrealized losses from Zcash price declines. Cypherpunk continues to focus on privacy technology and digital asset growth amid market volatility.
Coinbase shares have dropped nearly 50% over the past year, but a bullish case centers on a projected stablecoin market growth from $300 billion to $3 trillion by 2030. Coinbase's USD Coin and Base blockchain position it well to benefit from this exp...
Federal regulators finalized stablecoin rules under the GENIUS Act, prompting a surge in crypto stocks: Circle Internet Group rose 6%, Strategy jumped 8%, and Coinbase climbed 5%. The new rules set standards for reserve backing, redemption, and risk ...
JPMorgan has moved its dollar-backed JPM Coin to Ethereum's public blockchain, aiming to facilitate 24/7 institutional payments and tap into Ethereum's liquidity. Despite this major bank endorsement, Ethereum's price remains down, with no immediate u...
BlackRock's iShares Bitcoin Trust ETF (IBIT) operates through a Delaware statutory trust that legally owns the Bitcoin, with Coinbase acting as custodian holding the private keys. Shareholders hold beneficial interests, meaning they benefit from Bitc...
